EU Prepares To Reveal Pharma Strategy

Ambitious Proposals Are Due Out Next Week; Medicine Shortages Report Is Also On The Cards

The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.

European Union flag with covid-19 coronavirus in background
Future health threats are a key focus for EU • Source: Shutterstock

The European Commission will unveil its long-awaited EU pharmaceutical strategy on 24 November in an effort to improve access to affordable medicines and “harness the benefits of digital and emerging science and technology.” 

The strategy will address both short-term challenges related to COVID-19 “and of course longer-term challenges linked to unmet medical needs, strategic autonomy and sustainable health care systems,” EU health

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By 

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By 

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.